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Introduction
concentrations in the lymph nodes, it did provide an extended release of the parent nucleoside, resulting in sustained concentrations of d41
The nucleoside analogue 3'-deoxy-2',3'-didehydrothymidine (stavudine; d4T) suppresses the replication of human immunodeficiency virus (HIV) by inhibiting HIV reverse transcriptase. Cells which are susceptible to HIV infection are largely located in the lymphatic system (Pantaleo et al., 1993) . Thus, the lymphatic system is a primary target for early anti-HIV drug therapy. Strategies are being sought to enhance the delivery of nucleoside analogues such as zidovudine (AZT), zalcitabine (ddC) and d4T toward the lymph and lymph nodes. 5'-(3-sn-Phosphatidyl)-nucleosides have been proposed as lipophilic prodrugs which have a naturally high affinity for cell membranes. Thus, these prodrugs may facilitate transport of nucleosides into the lymphatic system and into cells, especially those which are infected by HIV (Shuto et al., 1988; Hostetler et al., 1990 Hostetler et al., , 1991 Muranishi, 1991) . By utilizing enzymes responsible for phospholipid metabolism, nucleosides can be liberated from the lipid prodrugs. For example, incubation of a phosphatidyl-AZTwith CEM cells in uitro resulted in the enzymatic formation of lysophosphatidyl-AZT, glycero-3-phospho-5'-AZT, AZT, AZT-MP, AZT-DP and AZT-TP (Hostetler et al., 1991) . Neither prodrug nor lipophilic metabolites inhibited HIV reverse transcriptase; however, they served as a depot and precursor of the active antiviral moiety. Furthermore, in vivo administration of phospholipid-PlIj/i. Z'T and -[3H] ddC in liposomal formulations to mice resulted in 100-fold increases in the area under the plasma radioactivity concentration versus time curve (AUC) relative to that of parent nucleosides KK Manouilov 1 , Z-S Xu 1, LS Manouilova I, FD Boudinotl, RF Schinozi? and CK Chu 1 *
The lymphatic system is a primary target for early antihuman immunodeficiency virus drug therapy. Strategies are currently being sought to enhance the delivery of nucleoside analogues such as 3'-deoxy-2',3'-didehydrothymidine (stavudine; d4T) toward the lymph and lymph nodes. The purpose of this study was to synthesize dipalmitoylphosphatidyl-d4T (DPP-d4T) as a lipophilic prodrug of d4T and to evaluate the lymphatic distribution of d4T following administration of d4T and DPp-d4T to mice. The pharmacokinetics of d4T were characterized following administration of a single intravenous or oral dose of 50 mg kg-1 d4T and an equimolar dose (214 mg kg-I) of DPP-d41 Concentrations of d4T in serum and lymph nodes were determined by HPLC. Following administration of d4T, the distribution of d4T into lymph nodes was rapid with maximum concentrations observed within 5 min after dosing. The AUC and half-life values of d4T in three groups of lymph nodes were similar to those in serum. Administration of DPp-d4T resulted in significantly lower concentrations of d4T in serum and lymph nodes. Approximately 67% of the intravenously administered DPP-d4T was biotransformed to parent compound. The apparent oral bioavailability of DPp-d4T was low. While the phospholipid prodrug did not increase d4T (Hostetler et al., 1994) . Following oral (p.o.) administration of dipalmitoylphosphatidylfluoro-uridine to rats, two major metabolites were identified; a palmitoyl at the 2 position of the glycerol moiety was reacylated by arachidonoyl or linoleoyl (Sakai et al., 1993) . Although lymph was found to contain only low levels of prodrug, congeners were detected at very high levels. Pharmacokinetic studies of phospholipid prodrugs of AZT, 3'-azido-2',3'dideoxyuridine (AZdU) and didanosine (ddI) revealed common alterations in parent nucleoside disposition made by the prodrug (Manouilov et al., 1995a,b) . These phospholipid prodrugs produced lower maximum but more sustained concentrations of the parent nucleosides in blood and lymph. The area-under-the-serum-nucleoside concentration versus time curves (AUC) were relatively unchanged by prodrug administration. Differences in lymphatic accumulation of the nucleosides were observed for each particular drug.
While d4T is structurally similar to AZT, differences in their profiles of metabolism, toxicity and clinical efficacy emphasize the distinctiveness of nucleoside analogues (Sommadossi, 1995) . Although the disposition of d4T in plasma has been extensively studied (Russell et al., 1990; Boudinot et al., 1991) no information is available regarding the lymphatic distribution of the nucleoside. The purpose of the present study was to evaluate the lymphatic distribution of d4T following administration of d4T and a phospholipid prodrug to mice.
Materials and Experimental Procedures
Chemicals Both d4T and 2',3'-dideoxy-3'-thiacytidine (3TC) were synthesized in our laboratories as previously described (Larsen et al., 1995; Choi et al., 1991; Hoong et al., 1992) . Dipalmitoylphosphatidyl-d4T (DPP-d4T) was synthesized as described below. The chemical purity of the compounds, as assessed by spectral and HPLC analysis, was greater than 99%.Dipalmitoyl-rac-glycerol (DPG) was obtained from Sigma. Dry dichloromethane and pyridine were obtained by distillation from CaH 2 prior to use.
Synthesis of phospholipid conjugates of d4T
The NMR spectra were recorded on a Bruker AMX 400 spectrometer using TMS as the internal standard for IH NMR and 85% H 3PO 4 as an external standard for 31p NMR; chemical shifts are reported in parts per million (0) and signals are quoted as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br s (broad singlet) and dd (doublet of doublet). TLC was performed on silica gel TLC Uniplates purchased from Analtech (Newark, Del., USA). Elemental analyses were performed by Atlantic Microlab (Norcross, Ga., USA). 410 An outline of the synthesis of phospholipid conjugates of d4T is shown in Fig. 1 . PC1 3 (1.422 mL, 16 mmol) was added to N-methyl morpholine (17.6 mL, 1600 mmol) in 160 mL dry CH 2C12 , followed by 1,2,4-triazole (3.68 g, 53.3 mmol). The mixture was stirred at room temperature for 30 min, then cooled to O°C.A solution of dipalmitoylrae-glycerol (1.822 g, 3.2 mmol) in anhydrous CH 2C12 (40 mL) was added dropwise over 10 min. The reaction mixture was stirred for 15 min, then poured into 150 mL 1.0 M TEAB buffer pH 7.2. The aqueous layer Was extracted with CH 2C12 (2x100 mL) and the combined organic layers were dried (Na 2SO 4) and concentrated. The residue was purified by silica gel column chromatography (CH 2C12:CHPH:NEt3 ; 95:3:2) to afford 1,2-dipalmitoyl-rac-glycero-3H-phosphonate triethyl ammonium salt (DPGP; 2.017 g, 86%): R f 0.52 (CH 2C12:CHPH:NEt3 ; 95:3:2); MS (ESI) 755.2 (M+NEt 3+Na)+; 31p NMR (CDC1 3 ) 0 5.24 (JP-H +630 Hz); IH NMR (CDC1 3 ) 0 12.48 (br s, 1H, D 2 0 exchangeable,NH+Et 3 ) [7.54 (s, 0.5 HO), 5.97 (s, 0.5 H), J p -H 630 Hz, P-H], 5.15 (rn, 1 H, CH-rac-2), 4.31 (dd, J 3.4, 11.9 Hz, 1 H, CH 2-rac-3a), 4.11 (dd,J 6.5,11.9 Hz, 1 H, CH 2-rac-3b), 3.92 (m, 2 H, CH 2-rac-1), 2.99 (q, 6 H, CH 2 of NEt 3 ) , 2.22 (rn, 4 H, . a-CH z), 1.52 (br s, 4 H, f)-CH z), 1.15-1.28 (rn, 57 H, 24 CH z and CH 3 ofNEt 3 ) 0.81 (t, 6 H, CH 3).
A mixture of d4T (303 mg, 1.35 mmol) and DPGP (900 mg, 1.23 mmol) was dried by coevaporation with pyridine three times and dissolved in 15 mL of anhydrous pyridine. Pivaloyl chloride (0.46 mL, 3.7 mmol) was added under argon and the mixture was stirred for 15 min. A solution of iodine (3% in pyridine:water; 4:1) was added to the reaction mixture until a stable brown colour of iodine was maintained. After 1.5 h, the excess iodine was reduced by the addition of saturated sodium thiosulphate solution. The mixture was evaporated and the residue was partitioned between 1 M TEAB buffer (100 mL) and CHClz (100 mL). The organic layer was dried (Na ZS04) and evaporated, the residue was purified by silica gel column chromatography (CH zClz:CH30H:NEt3 ; 95:3:2) and then lyophilized from 10 mL cyclohexane to afford 
Experimental design
Female NIH-Swiss mice (Harlan Sprague-Dawley, Indianapolis, Ind., USA) weighing 24-26 g were used for pharmacokinetic experiments. Mice were maintained at the University of Georgia College of Pharmacy Animal Care Facility, which is fully accredited by the American Association for the Accreditation of Laboratory Animal Care. The mice were acclimatized in a 12 h light-12 h dark constant temperature (22°C) environment with free access to standard laboratory chow and water for 1 week prior to the experiments. Animal studies were approved by the University of Georgia Animal Care and Use Committee, and conducted in accordance with guidelines established by the Animal Welfare Act and the National Institutes of Health (Anonymous, 1996) .
The pharmacokinetics of d4T were characterized following single intravenous (i.v.) and p.o. dose administration of 50 mg kg~l d4T and following the administration of an equimolar dose (214 mg kg-I) ofDPP-d4T. For i.v. administration, d4T (12.5 mg mL-1) was dissolved in physiological saline and injected through a tail vein over Antiviral Chemistry & Chemotherapy 8(5) Lymphatic targeting of anti-HIV nucleosides 1 min. For p.o. administration, d4T (6.25 mg mL-l) dissolved in water was administered by gastric gavage. DPP-d4T solution (26.75 mg mL-l) was prepared by sonication of the compound in water at 22°C using a Special Ultrasonic Cleaner (Laboratory Supplies Company, Hicksville, N.Y., USA). Then, 200 ul. of the solution was administered intravenously through a tail vein over 2-3 min or orally by gastric gavage. Animals were placed in individual cages and allowed food and water ad libitum. Mice (three animals at each time point) were anaesthetized with diethyl ether and sacrificed by exsanguination via a left ventricle heart puncture at 5, 15, 30 and 45 min, 1,2,3,4,6,9,12 and 15 h after drug administration. Blood (serum) and neck (NLN), axillary (ALN) and mesenteric (MLN) lymph nodes were collected and immediately analysed for nucleoside content.
Analytical methodology
Concentrations of d4T in serum were determined by HPLC as previously described (Boudinot et al, 1991) . Briefly, in a 1.5 mL polypropylene microcentrifuge tube, serum (200~tL), 50~L of internal standard (13~g mL-l 3TC) and 50 ul, of 2 M perchloric acid were mixed. The tubes were vortexed and centrifuged at 5000 g. An aliquot of supernatant (15 to 50 u.L) was injected onto the column.
Concentrations of d4T in lymph nodes were determined as follows. In 12x75 mm glass culture tubes, lymph nodes were homogenized in 300~tL ice-cold water containing internal standard (50 ul.), Acetonitrile (1.8 mL) was added to precipitate proteins and tubes were centrifuged at 4000 g for 30 min at 4°C. The supernatant was transferred to clean tubes and dried under a stream of nitrogen gas at 22°C. The residue was reconstituted in 120 tL mobile phase and after centrifugation at 4000 g for 30 min, 25-50 ul. was injected onto the HPLC.
Chromatographic separations were performed on a Shimadzu LC-10A series analyticalHPLC system equipped with a Hypersil ODS column (250x4.6 mm, 5 urn particle size; Alltech Associates, Deerfield, Ill., USA) preceded by a guard column packed with~tBondapak C18 precolumn insert (Waters Associates,Milford, Mass., USA). The mobile phase consisted of 4% (v/v) acetonitrile in 5 mM KzHP0 4 and 5 mM triethylamine.The flow rate of the mobile phase was 1.5 mL min-I. The UV detection wavelength was 270 nm (0.001 AUFS). d4T and internal standard retention times were 12.0 and 7.2 min, respectively. The limit of quantification for d4T was 0.1~tg mL-1 (or~tg g-l) in each biological media. The intra-and inter-assay relative standard deviations were less than 7% in serum and tissue homogenates.
Data analysis
Mean serum, NLN, ALN and MLN drug concentration versus time data were analysed by non-compartmental techniques. The area under the serum and lymph node concen-tration versus time curves (AUC) and the first nonnormalized moments (AUMC) were determined by Lagrange polynomial interpolation and integration from time zero to the last sample time (Rocci & jusko, 1983) with extrapolation to time infinity using the weighted (l/C) least-squares (RSTRIP) terminal slope (A.). Standard deviation values of concentrations and A. z were used to calculate the variance of estimated AUC values (Yuan, 1993) . Halflife was calculated from 0.693/A. z . For intravenously administered d4T, total clearance (CLy) was calculated from dose!AUC and steady-state volume of distribution (V ss ) from dosexAUMCI AUC2. The bioavailabilty (F) of d4T following p.o. administration was calculated from 
Results
Concentrations of d4T in serum and lymph nodes as a function of time following i.v. administration of 50 mg kg-1 d4T to mice (three animals at each time point) are illustrated in Fig. 2(a) . The maximum observed d4T Concentration in serum (60±2.3 [,tg mL-I), ALN (59±6.1 [,tg g-I), MLN (69±2.5~lg g-I) and NLN (66±13 [,tg g-I) were observed at 5 min after dosing. d4T exhibited similar kinetic profiles in serum and lymph nodes with elimination half-lives ranging between 0.26 and 0.38 h (Table 1) . AUC values in serum and lymph nodes were also similar (24.8-30.3 mg h L-I). The relative exposure values of d4T in lymph nodes, as compared to serum, were slightly greater than unity (1.1-1.2) . The total clearance and steady-state volume of distribution of d4T were 2.01 L h-I kg-I and 0.75 L kg-I, respectively.
Following p.o. administration, d4T was rapidly absorbed and reached a maximum concentration of 27±8.7 [,tg mL-l in serum, 25±12 [,tg g-I in ALN and 18±4.9 [,tg g-l in MLN by 15 min (Fig. 2b) AVe values in serum and lymph nodes were similar (17.8-24.0 mg h L-i). The absolute bioavailability of d4T was 91%. In contrast to the relative exposure values of greater than unity seen for lymph nodes following i.v, administration, r e values for each lymph node following p.o. administration of d4T were less than unity. Relative exposure values in NLN, ALN and MLN were 0.74, 0.88 and 0.82, respectively. Fig. 2(c) depicts the concentration-time profiles of d4T in serum and lymph nodes following i.v. administration of 214 mg kg-i DPP-d4T. Maximum concentrations of d4T in serum (3.6±0.3 /-Lg mL-i) and NLN (3.3±2~tg g-i) were detected at 1 h while in ALN (3.5±0.5 /-Lg g-i) and MLN (3.4±0.6 /-Lg g-i) maximum levels were reached at 2 h after prodrug administration. Half-lives ranged from 3.5 to 7.3 h (Table 1) . AVe values in serum and lymph nodes were similar, ranging from 14.2 to 18.2 mg h L". The relative exposure values of d4T in lymph nodes, as compared to serum, were approximately unity (0.85-1.1). The AVe of d4T released from prodrug in serum was 67% of that when administered intravenously as parent drug. Similar ratios were observed for NLN (0.67) and MLN (0.64); however, a lower ratio (0.47) was noted for ALN.
The disposition pattern of d4T after p.o. administration of DPP-d4T is shown in Fig. 2(d) . Maximum concentrations of d4T in serum and lymph nodes did not exceed 2~tg mL-i. Following DPP-d4T administration the value for AVe of d4T in serum was 23% of that following p.o. administration of d4T. Similarly, the AVe values in lymph nodes following p.o. administration of DPP-d4T were approximately one-third of those seen after i.v, administration of the prodrug. However, relative nucleoside exposure in lymphatic tissue (1.2 to 1.5) was higher than that after p.o. administration of d4T itself. The half-life values ranged from 2 to 4.5 h (Table 1) 
Discussion
The disposition of d4T in mice following i.v. and p.o. administration observed in this study was similar to that previously reported (Russell et a!., 1990) . The total clearance of d4T (2.01 L h-i kg-i) was moderate relative to hepatic (6 L h-i kg-i) and renal (4.4 L h-i kg-i) blood flow rates in the mouse (Gerlowski & Jain, 1983) . The steady-state volume of distribution (0.75 L kg-i) of d4T approximated to total body water (0.7 L kg-i). The nucleoside was well absorbed following p.o. administration with a bioavailability of 91%. The twofold greater terminal phase half-life of d4T following p.o. administration (31 min) compared to that following i.v. administration (16 min) suggests that absorption of d4T from the gastrointestinal tract is rate-limiting.
The distribution of d4T into lymph nodes was rapid with maximum concentrations observed within 5 min after d4T administration. Pharmacokinetic profiles of d4T in lymph nodes were well correlated with serum levels after i.v. and p.o. administration. The AVe and half-life values of d4T in the lymph nodes were similar to those in serum. The relative lymph node exposure of d4T was greater than that reported for other nucleosides (Manouilov et al., 1995a (Manouilov et al., , 1997 . Interestingly, the distribution of nucleoside analogues into lymph nodes appears to be inversely related to lipophilicity as assessed by the partition coefficient (k p ) ' Reported relative lymph node exposure values for nucleoside analogues are 0.43 for AZT (k 1.1; Manouilov et a!., p 1995a), 0.60 for AZdV (k p 0.45; Manouilov et al., 1995a) , 0.86 for ddI (k p 0.07; Ford et a!., 1991; Manouilov et~!., 1997) ,0.88 for dde (~0.03; Hostetler et al., 1994; Ibrahim et al., 1996) and 1.1 for d4T (k p 0.11; Boudinot eta!., 1991) .
Thus, it appears that the more hydrophilic nucleoside analogues distribute into lymph nodes to a greater extent than do less hydrophilic analogues.
It is also interesting to note that there are regional differences in the lymph node distribution of AZT and AZdU (Manouilov et al., 1995a) . The distribution of these compounds into the ALN is two-to threefold greater than distribution into NLN and MLN. No regional differences in the lymphatic distribution of ddI (Manouilov et al., 1997) or d4T were observed. The route of administration appears to playa variable role in the distribution of nucleosides into the lymphatic system. Lymph node exposure to AZT was similar following i.v. and p.o. administration of AZT. However, for AZdU and d4T, greater lymph node exposure was observed following i.v. administration of nucleoside. Contrasting results were noted for ddI, where approximately a twofold greater lymph node exposure was seen following p.o. administration as compared to that following i.v. administration. Taken together, these results suggest that the distribution of nucleoside analogues into the lymphatic system may involve specific carrier-mediated mechanisms.
A new lipophilic prodrug, DPP-d4T, was synthesized with the aim to provide appreciable lymphatic delivery of d4T. Both i.v. and p.o. administration of DPP-d4T resulted in significantly lower concentrations of d4T in serum and lymph nodes. Conversion of the prodrug to d4T was incomplete; approximately 67% of the intravenously administered DPP-d4T was biotransformed to parent compound. The apparent oral bioavailabilty ofDPP-d4T, based on d4T concentrations, was low. The AUC for d4T following p.o. administration of DPP-d4T was threefold lower than that following i.v. administration of the prodrug and fourfold lower than the d4T AUC following p.o. administration of parent nucleoside. However, the relative nucleoside exposure in the lymph nodes following p.o. administration of prodrug was greater than after p.o. administration of d4T. Thus, DPP-d4T may be absorbed directly into the lymphatic system from the gastrointestinal tract.
While the phospholipid prodrug did not increase d4T concentrations in the lymph nodes, it did provide an extended release of the parent nucleoside, resulting in sustained concentrations of d4T. The apparent half-life of d4T was increased approximately 10-fold following i.v. administration of DPP-d4T and about fourfold following p.o. administration of the prodrug. Similar results have been reported for phospholipid prodrugs of AZT (Manouilov et al., 1995a) , AZdU (Manouilov et al., 1995a) , ddI (Manouilov et al., 1997) and ddC (Hostetler et al., 1994) . Thus, while the dipalmitoylphosphatidyl-nucleoside prodrugs DPP-AZT, DPP-AZdU and DPP-ddI improved delivery of the parent nucleosides to the lymphatic system, DPP-d4T did not. Similar to the other dipalmitoylphosphatidyl-nucleoside prodrugs, however, DPP-d4T produced more sustained concentrations of d4T.
The apparent bioavailability of d4T from DPP-d4T administration was 67% and 23%, following i.v. and p.o. administration of prodrug, respectively. This is higher than that reported for DPP-ddI where the apparent bioavail-414 ability of ddI released from DPP-ddI was 15% following i.v. administration of prodrug and 8% following p.o. administration (Manouilov et al., 1997) . The apparent bioavailability of DPP-d4T was similar to that for AZT release from DPP-AZT (56% following i.v. administration and 49% after p.o. administration of prodrug; Manouilov et al., 1995b) .
In conclusion, the results of this study show that d4T distributes into the lymphatic system to a greater extent than does AZT, AZdU, ddI or ddC. DPP-d4T did not improve lymphatic distribution of d4T; however the prodrug provided more sustained concentrations of parent nucleoside.
